NSG 552 Exam 2 WU Psychopharmacology - 2026/2027
Edition | 200 Verified Questions - 193 Questions with Answers
NSG 552 Exam 2 Psychopharmacology 2026-193 QUESTIONS AND ANSWERS ALREADY GRADED A+. 100%
Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document for NSG 552 Exam 2 focuses on
psychopharmacology, covering the principles of pharmacodynamics and pharmacokinetics, major drug
classes, and their clinical applications in psychiatric care. It includes 200 verified questions with
detailed rationales, designed to reinforce critical thinking and ensure mastery of the subject. The
content is aligned with the latest 2026/2027 academic guidelines and evidence-based practices, making
it an essential resource for nursing students.
Key Features:
Foundations of Psychopharmacology: Neurotransmission, receptor binding, and drug-receptor interactions
Pharmacokinetics and Pharmacodynamics: Absorption, distribution, metabolism, excretion, and dose-response
relationships
Antidepressants: SSRIs, SNRIs, TCAs, MAOIs, and atypical antidepressants
Antipsychotics: First-generation (typical) and second-generation (atypical) agents
Mood Stabilizers: Lithium, valproate, lamotrigine, and other anticonvulsants
Anxiolytics and Sedative-Hypnotics: Benzodiazepines, buspirone, and Z-drugs
Stimulants and ADHD Medications: Methylphenidate, amphetamines, and non-stimulant options
Cognitive Enhancers: Donepezil, memantine, and other agents for dementia
Substance Use Disorder Medications: Nicotine replacement, buprenorphine, naltrexone, and acamprosate
Special Populations: Pediatric, geriatric, and pregnancy/lactation considerations
Adverse Effects and Drug Interactions: Common side effects, serious adverse reactions, and cytochrome P450
interactions
Patient Education and Monitoring: Adherence, therapeutic drug monitoring, and suicide risk assessment
Evidence-Based Practice and Guidelines: APA, NICE, and other clinical guidelines
Case-Based Application: Integrating psychopharmacology into clinical scenarios
Legal and Ethical Considerations: Informed consent, off-label use, and prescriptive authority
Cultural and Psychosocial Factors: Impact on medication response and adherence
Recent Advances and Emerging Therapies: Novel agents and future directions
Exam Strategies and Test-Taking Tips: Approaches to multiple-choice questions and rationales
Updates for 2026:
- Updated to reflect the latest 2026/2027 DSM-5-TR and APA guidelines
- Incorporated recent FDA approvals and black-box warnings
- Enhanced rationales with evidence-based references and clinical pearls
- Added new questions on emerging psychopharmacological agents
- Revised to include updated safety and monitoring parameters
Abstract:
This exam preparation document is meticulously crafted for NSG 552 Exam 2, focusing on the advanced practice
nursing management of psychiatric disorders through pharmacotherapy. It integrates core principles of
neurobiology with clinical applications, emphasizing the selection, dosing, and monitoring of psychotropic
medications. The content is organized to mirror the course curriculum, covering major drug classes, their
mechanisms of action, therapeutic indications, and adverse effect profiles. Special attention is given to vulnerable
Page 1
,populations, drug-drug interactions, and evidence-based prescribing practices. Each question is accompanied by a
detailed rationale that explains the correct answer and distracts, fostering a deeper understanding of the material.
This resource is designed to enhance critical thinking and prepare students for both the exam and clinical practice.
Keywords:
Psychopharmacology, NSG 552, Exam 2, Nursing, Psychotropic drugs, Pharmacokinetics, Pharmacodynamics,
Clinical guidelines
Answer Format:
Each question is followed by the correct answer and a comprehensive rationale explaining why it is correct and
why the other options are incorrect. Rationales include clinical implications, pharmacokinetic/pharmacodynamic
principles, and relevant guidelines to reinforce learning.
Compliance Checklist:
Aligned with 2026/2027 academic year and latest evidence-based guidelines
200 verified questions with accurate answers and detailed rationales
Covers all major content areas of NSG 552 Exam 2 psychopharmacology
Includes updates on recent FDA approvals and safety warnings
Designed to promote critical thinking and clinical reasoning
Suitable for self-assessment and exam preparation
Content Area Overview:
Content Area Questions Key Topics Weight
Foundations of 1-20 Neurotransmission, receptor binding, 10%
Psychopharmacology drug-receptor interactions
Pharmacokinetics and 21-40 ADME, dose-response, therapeutic drug 10%
Pharmacodynamics monitoring
Antidepressants 41-70 SSRIs, SNRIs, TCAs, MAOIs, atypical 15%
agents
Antipsychotics 71-100 First-generation, second-generation, EPS, 15%
metabolic effects
Mood Stabilizers 101-120 Lithium, valproate, lamotrigine, monitoring 10%
Anxiolytics and 121-140 Benzodiazepines, buspirone, Z-drugs, 10%
Sedative-Hypnotics dependence
Stimulants and ADHD 141-155 Methylphenidate, amphetamines, 7.5%
Medications non-stimulants, abuse potential
Cognitive Enhancers 156-165 Cholinesterase inhibitors, memantine, 5%
dementia management
Substance Use Disorder 166-175 Nicotine replacement, buprenorphine, 5%
Medications naltrexone, acamprosate
Special Populations 176-185 Pediatric, geriatric, pregnancy/lactation 5%
considerations
Adverse Effects and Drug 186-195 Serotonin syndrome, QT prolongation, 5%
Interactions CYP450 interactions
Patient Education and 196-200 Adherence, suicide risk, therapeutic drug 2.5%
Monitoring monitoring
Page 2
,Q1. A patient with treatment-resistant depression is being switched from phenelzine
to vortioxetine. What is the minimum required washout period, and why?
A. 14 days; to allow MAO-A enzyme regeneration
B. 7 days; to allow MAO-B enzyme regeneration
C. 5 half-lives of phenelzine; to eliminate active metabolites
D. No washout needed if vortioxetine is started at a low dose
Correct Answer: A. 14 days; to allow MAO-A enzyme regeneration
Rationale: The required washout is 14 days after stopping an MAOI before starting a
serotonergic agent to allow MAO-A regeneration and prevent serotonin syndrome. A
7-day washout is insufficient for MAO-A recovery, and 5 half-lives of phenelzine is not the
standard clinical rule. Starting vortioxetine without a washout risks severe serotonin
toxicity.
Why Wrong:
B - MAO-B inhibition is less relevant to serotonin toxicity; the critical enzyme is
MAO-A, and 7 days is insufficient for its regeneration.
C - The washout period is based on enzyme regeneration, not drug half-life;
phenelzine's active metabolite, although present, is not the primary determinant.
D - No washout is unsafe; even low-dose vortioxetine can precipitate serotonin
syndrome if MAO-A is still inhibited.
Reference: Stahl, S. M. (2021). Stahl's Essential Psychopharmacology, 5th ed., Ch. 8
Q2. Which pharmacogenomic variant most strongly predicts poor response to
CYP2D6-metabolized antipsychotics, and what clinical action is recommended?
A. CYP2D6 ultrarapid metabolizer phenotype; increase dose to achieve therapeutic
levels
B. CYP2D6 poor metabolizer phenotype; reduce dose or choose a
non-CYP2D6-dependent agent
C. CYP1A2 *1F variant; avoid smoking cessation due to enzyme induction
D. CYP3A4 poor metabolizer phenotype; monitor for QT prolongation
Correct Answer: B. CYP2D6 poor metabolizer phenotype; reduce dose or choose a
non-CYP2D6-dependent agent
Rationale: CYP2D6 poor metabolizers have reduced metabolism of many antipsychotics
(e.g., risperidone, haloperidol), leading to higher plasma concentrations and increased
adverse effects. The clinical recommendation is to reduce the dose or select an agent not
primarily metabolized by CYP2D6. Ultrarapid metabolizers may need higher doses, but
that is not the strongest predictor of poor response. CYP1A2 and CYP3A4 variants are
less directly linked to antipsychotic response.
Why Wrong:
A - Ultrarapid metabolizers may require higher doses, but this is not the variant most
Page 3
, strongly associated with poor response; they often respond adequately with dose
adjustment.
C - CYP1A2 *1F affects clozapine and olanzapine metabolism, but smoking cessation
decreases clearance, not increases; this is not the strongest predictor.
D - CYP3A4 poor metabolizers may have increased levels of some antipsychotics, but
CYP2D6 is the more clinically significant variant for antipsychotic response.
Reference: CPIC Guideline for CYP2D6 and Antipsychotics (2023)
Q3. A patient with bipolar depression is already on lamotrigine 200 mg/day and
presents with acute depressive episode. Which adjunctive strategy is most
evidence-based?
A. Add aripiprazole 10 mg/day
B. Add lurasidone 20 mg/day
C. Increase lamotrigine to 400 mg/day
D. Add quetiapine 300 mg/day
Correct Answer: B. Add lurasidone 20 mg/day
Rationale: Lurasidone is FDA-approved for bipolar depression and has strong evidence
as monotherapy or adjunctive therapy. Aripiprazole is more effective for mania, not
depression. Increasing lamotrigine above 200 mg is not evidence-based and increases
adverse effects. Quetiapine is effective but its sedative and metabolic side effects make
lurasidone a preferred adjunctive option.
Why Wrong:
A - Aripiprazole is not effective for bipolar depression; it is indicated for mania and
maintenance.
C - Lamotrigine doses above 200 mg are not supported by evidence and increase risk
of adverse effects.
D - Quetiapine is effective, but lurasidone has a more favorable metabolic profile and
is equally evidence-based.
Reference: Yatham, L. N., et al. (2018). CANMAT/ISBD Bipolar Disorder Guidelines, Am
J Psychiatry
Q4. A patient with generalized anxiety disorder and hepatic impairment (Child-Pugh
B) is started on buspirone. What is the recommended dose adjustment?
A. No adjustment needed; buspirone is hepatically metabolized but safe
B. Reduce dose to 2.5 mg twice daily
C. Use a maximum of 15 mg/day in divided doses
D. Avoid buspirone entirely due to risk of hepatic encephalopathy
Correct Answer: C. Use a maximum of 15 mg/day in divided doses
Page 4
Edition | 200 Verified Questions - 193 Questions with Answers
NSG 552 Exam 2 Psychopharmacology 2026-193 QUESTIONS AND ANSWERS ALREADY GRADED A+. 100%
Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document for NSG 552 Exam 2 focuses on
psychopharmacology, covering the principles of pharmacodynamics and pharmacokinetics, major drug
classes, and their clinical applications in psychiatric care. It includes 200 verified questions with
detailed rationales, designed to reinforce critical thinking and ensure mastery of the subject. The
content is aligned with the latest 2026/2027 academic guidelines and evidence-based practices, making
it an essential resource for nursing students.
Key Features:
Foundations of Psychopharmacology: Neurotransmission, receptor binding, and drug-receptor interactions
Pharmacokinetics and Pharmacodynamics: Absorption, distribution, metabolism, excretion, and dose-response
relationships
Antidepressants: SSRIs, SNRIs, TCAs, MAOIs, and atypical antidepressants
Antipsychotics: First-generation (typical) and second-generation (atypical) agents
Mood Stabilizers: Lithium, valproate, lamotrigine, and other anticonvulsants
Anxiolytics and Sedative-Hypnotics: Benzodiazepines, buspirone, and Z-drugs
Stimulants and ADHD Medications: Methylphenidate, amphetamines, and non-stimulant options
Cognitive Enhancers: Donepezil, memantine, and other agents for dementia
Substance Use Disorder Medications: Nicotine replacement, buprenorphine, naltrexone, and acamprosate
Special Populations: Pediatric, geriatric, and pregnancy/lactation considerations
Adverse Effects and Drug Interactions: Common side effects, serious adverse reactions, and cytochrome P450
interactions
Patient Education and Monitoring: Adherence, therapeutic drug monitoring, and suicide risk assessment
Evidence-Based Practice and Guidelines: APA, NICE, and other clinical guidelines
Case-Based Application: Integrating psychopharmacology into clinical scenarios
Legal and Ethical Considerations: Informed consent, off-label use, and prescriptive authority
Cultural and Psychosocial Factors: Impact on medication response and adherence
Recent Advances and Emerging Therapies: Novel agents and future directions
Exam Strategies and Test-Taking Tips: Approaches to multiple-choice questions and rationales
Updates for 2026:
- Updated to reflect the latest 2026/2027 DSM-5-TR and APA guidelines
- Incorporated recent FDA approvals and black-box warnings
- Enhanced rationales with evidence-based references and clinical pearls
- Added new questions on emerging psychopharmacological agents
- Revised to include updated safety and monitoring parameters
Abstract:
This exam preparation document is meticulously crafted for NSG 552 Exam 2, focusing on the advanced practice
nursing management of psychiatric disorders through pharmacotherapy. It integrates core principles of
neurobiology with clinical applications, emphasizing the selection, dosing, and monitoring of psychotropic
medications. The content is organized to mirror the course curriculum, covering major drug classes, their
mechanisms of action, therapeutic indications, and adverse effect profiles. Special attention is given to vulnerable
Page 1
,populations, drug-drug interactions, and evidence-based prescribing practices. Each question is accompanied by a
detailed rationale that explains the correct answer and distracts, fostering a deeper understanding of the material.
This resource is designed to enhance critical thinking and prepare students for both the exam and clinical practice.
Keywords:
Psychopharmacology, NSG 552, Exam 2, Nursing, Psychotropic drugs, Pharmacokinetics, Pharmacodynamics,
Clinical guidelines
Answer Format:
Each question is followed by the correct answer and a comprehensive rationale explaining why it is correct and
why the other options are incorrect. Rationales include clinical implications, pharmacokinetic/pharmacodynamic
principles, and relevant guidelines to reinforce learning.
Compliance Checklist:
Aligned with 2026/2027 academic year and latest evidence-based guidelines
200 verified questions with accurate answers and detailed rationales
Covers all major content areas of NSG 552 Exam 2 psychopharmacology
Includes updates on recent FDA approvals and safety warnings
Designed to promote critical thinking and clinical reasoning
Suitable for self-assessment and exam preparation
Content Area Overview:
Content Area Questions Key Topics Weight
Foundations of 1-20 Neurotransmission, receptor binding, 10%
Psychopharmacology drug-receptor interactions
Pharmacokinetics and 21-40 ADME, dose-response, therapeutic drug 10%
Pharmacodynamics monitoring
Antidepressants 41-70 SSRIs, SNRIs, TCAs, MAOIs, atypical 15%
agents
Antipsychotics 71-100 First-generation, second-generation, EPS, 15%
metabolic effects
Mood Stabilizers 101-120 Lithium, valproate, lamotrigine, monitoring 10%
Anxiolytics and 121-140 Benzodiazepines, buspirone, Z-drugs, 10%
Sedative-Hypnotics dependence
Stimulants and ADHD 141-155 Methylphenidate, amphetamines, 7.5%
Medications non-stimulants, abuse potential
Cognitive Enhancers 156-165 Cholinesterase inhibitors, memantine, 5%
dementia management
Substance Use Disorder 166-175 Nicotine replacement, buprenorphine, 5%
Medications naltrexone, acamprosate
Special Populations 176-185 Pediatric, geriatric, pregnancy/lactation 5%
considerations
Adverse Effects and Drug 186-195 Serotonin syndrome, QT prolongation, 5%
Interactions CYP450 interactions
Patient Education and 196-200 Adherence, suicide risk, therapeutic drug 2.5%
Monitoring monitoring
Page 2
,Q1. A patient with treatment-resistant depression is being switched from phenelzine
to vortioxetine. What is the minimum required washout period, and why?
A. 14 days; to allow MAO-A enzyme regeneration
B. 7 days; to allow MAO-B enzyme regeneration
C. 5 half-lives of phenelzine; to eliminate active metabolites
D. No washout needed if vortioxetine is started at a low dose
Correct Answer: A. 14 days; to allow MAO-A enzyme regeneration
Rationale: The required washout is 14 days after stopping an MAOI before starting a
serotonergic agent to allow MAO-A regeneration and prevent serotonin syndrome. A
7-day washout is insufficient for MAO-A recovery, and 5 half-lives of phenelzine is not the
standard clinical rule. Starting vortioxetine without a washout risks severe serotonin
toxicity.
Why Wrong:
B - MAO-B inhibition is less relevant to serotonin toxicity; the critical enzyme is
MAO-A, and 7 days is insufficient for its regeneration.
C - The washout period is based on enzyme regeneration, not drug half-life;
phenelzine's active metabolite, although present, is not the primary determinant.
D - No washout is unsafe; even low-dose vortioxetine can precipitate serotonin
syndrome if MAO-A is still inhibited.
Reference: Stahl, S. M. (2021). Stahl's Essential Psychopharmacology, 5th ed., Ch. 8
Q2. Which pharmacogenomic variant most strongly predicts poor response to
CYP2D6-metabolized antipsychotics, and what clinical action is recommended?
A. CYP2D6 ultrarapid metabolizer phenotype; increase dose to achieve therapeutic
levels
B. CYP2D6 poor metabolizer phenotype; reduce dose or choose a
non-CYP2D6-dependent agent
C. CYP1A2 *1F variant; avoid smoking cessation due to enzyme induction
D. CYP3A4 poor metabolizer phenotype; monitor for QT prolongation
Correct Answer: B. CYP2D6 poor metabolizer phenotype; reduce dose or choose a
non-CYP2D6-dependent agent
Rationale: CYP2D6 poor metabolizers have reduced metabolism of many antipsychotics
(e.g., risperidone, haloperidol), leading to higher plasma concentrations and increased
adverse effects. The clinical recommendation is to reduce the dose or select an agent not
primarily metabolized by CYP2D6. Ultrarapid metabolizers may need higher doses, but
that is not the strongest predictor of poor response. CYP1A2 and CYP3A4 variants are
less directly linked to antipsychotic response.
Why Wrong:
A - Ultrarapid metabolizers may require higher doses, but this is not the variant most
Page 3
, strongly associated with poor response; they often respond adequately with dose
adjustment.
C - CYP1A2 *1F affects clozapine and olanzapine metabolism, but smoking cessation
decreases clearance, not increases; this is not the strongest predictor.
D - CYP3A4 poor metabolizers may have increased levels of some antipsychotics, but
CYP2D6 is the more clinically significant variant for antipsychotic response.
Reference: CPIC Guideline for CYP2D6 and Antipsychotics (2023)
Q3. A patient with bipolar depression is already on lamotrigine 200 mg/day and
presents with acute depressive episode. Which adjunctive strategy is most
evidence-based?
A. Add aripiprazole 10 mg/day
B. Add lurasidone 20 mg/day
C. Increase lamotrigine to 400 mg/day
D. Add quetiapine 300 mg/day
Correct Answer: B. Add lurasidone 20 mg/day
Rationale: Lurasidone is FDA-approved for bipolar depression and has strong evidence
as monotherapy or adjunctive therapy. Aripiprazole is more effective for mania, not
depression. Increasing lamotrigine above 200 mg is not evidence-based and increases
adverse effects. Quetiapine is effective but its sedative and metabolic side effects make
lurasidone a preferred adjunctive option.
Why Wrong:
A - Aripiprazole is not effective for bipolar depression; it is indicated for mania and
maintenance.
C - Lamotrigine doses above 200 mg are not supported by evidence and increase risk
of adverse effects.
D - Quetiapine is effective, but lurasidone has a more favorable metabolic profile and
is equally evidence-based.
Reference: Yatham, L. N., et al. (2018). CANMAT/ISBD Bipolar Disorder Guidelines, Am
J Psychiatry
Q4. A patient with generalized anxiety disorder and hepatic impairment (Child-Pugh
B) is started on buspirone. What is the recommended dose adjustment?
A. No adjustment needed; buspirone is hepatically metabolized but safe
B. Reduce dose to 2.5 mg twice daily
C. Use a maximum of 15 mg/day in divided doses
D. Avoid buspirone entirely due to risk of hepatic encephalopathy
Correct Answer: C. Use a maximum of 15 mg/day in divided doses
Page 4
